Candel Therapeutics, INC Form 4 insider transactions

Candel Therapeutics, Inc. Director Nicoletta Loggia has reported the acquisition of 2,141 shares of common stock at $4.67 per share through a registered direct offering, as disclosed in a recent SEC Form 4 filing.

Candel Therapeutics, Inc. Director Gary J. Nabel has acquired 5,353 shares of common stock at $4.67 per share through a registered direct offering.

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, Inc., acquired 4,282 shares of common stock at $4.67 per share through a registered direct offering.

Candel Therapeutics, Inc. Director Joseph C. Papa acquired 64,239 shares of common stock through a registered direct offering at $4.67 per share, held indirectly by his revocable living trust.

Candel Therapeutics' Chief Financial Officer, Charles Schoch, was granted 50,000 stock options with a $4.75 exercise price, vesting over four years.

Candel Therapeutics, Inc. Director Edward J. Benz Jr. was granted 14,240 stock options with an exercise price of $4.94, subject to time-based vesting.

Candel Therapeutics, Inc. Director Renee Gaeta was granted 14,240 stock options with an exercise price of $4.94, subject to time-based vesting conditions.

Candel Therapeutics, Inc. Director Nicoletta Loggia was granted 14,240 stock options with an exercise price of $4.94, vesting over time.

Candel Therapeutics, Inc. Director Paul B. Manning has acquired 14,240 stock options with an exercise price of $4.94, vesting based on time or the next Annual Meeting of Stockholders.

Candel Therapeutics, Inc. Director Christopher Martell was granted 14,240 stock options with an exercise price of $4.94, set to vest by June 2026.

Candel Therapeutics, Inc. Director Gary J. Nabel was granted 14,240 stock options with an exercise price of $4.94, vesting over time.

Candel Therapeutics, Inc. Director Diem Nguyen was granted 14,240 stock options with an exercise price of $4.94, aligning her interests with shareholders.

Candel Therapeutics, Inc. Director Joseph C. Papa was granted 14,240 stock options with an exercise price of $4.94, vesting based on time or the next annual meeting.

Maha Radhakrishnan, a Director at Candel Therapeutics, Inc., was granted 28,480 stock options with an exercise price of $5.60, vesting over 36 months.

William Garrett Nichols, Chief Medical Officer of Candel Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, exercised stock options and sold shares on March 18, 2025, according to a Form 4 filing with the SEC.

Candel Therapeutics CEO Paul Peter Tak sold a portion of his common stock holdings on March 18th and 19th, 2025, under a pre-arranged 10b5-1 trading plan.

Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, sold 31,278 shares of common stock at an average price of $8.8224 under a pre-arranged 10b5-1 trading plan.

Charles Schoch, Interim CFO of Candel Therapeutics, sold 5,000 shares of common stock at an average price of $8.8338 on March 17, 2025, under a pre-arranged 10b5-1 trading plan.

Director Estuardo Aguilar-Cordova reports the sale of Candel Therapeutics shares held directly and indirectly through trusts.

Charles Schoch, Interim CFO of Candel Therapeutics, acquired 83,000 stock options on February 12, 2025, according to a recent SEC filing.

William Garrett Nichols, Chief Medical Officer of Candel Therapeutics, Inc., was granted stock options exercisable for 107,250 shares of common stock on February 12, 2025, according to a Form 4 filing with the SEC.

Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, receives stock options for 65,000 shares.

Paul Peter Tak, CEO of Candel Therapeutics, was granted stock options for 525,000 shares on February 12, 2025, vesting monthly over four years.

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, receives stock options grant.

Director Estuardo Aguilar-Cordova reports the disposition of Candel Therapeutics shares, while also detailing beneficial ownership through various trusts.

Francesca Barone, Chief Scientific Officer of Candel Therapeutics, sold 13,534 shares of common stock on January 15, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.

Charles Schoch, Interim CFO of Candel Therapeutics, sold 9,511 shares of common stock on January 15, 2025, at a price of $7.225 per share to cover tax withholding obligations related to vesting restricted stock units.